GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virpax Pharmaceuticals Inc (NAS:VRPX) » Definitions » Price-to-Owner-Earnings

Virpax Pharmaceuticals (Virpax Pharmaceuticals) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Virpax Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-06-09), Virpax Pharmaceuticals's share price is $0.7501. Virpax Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Virpax Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


VRPX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), Virpax Pharmaceuticals's share price is $0.7501. Virpax Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-14.42. Therefore, Virpax Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-06-09), Virpax Pharmaceuticals's share price is $0.7501. Virpax Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-14.42. Therefore, Virpax Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Virpax Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Virpax Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virpax Pharmaceuticals Price-to-Owner-Earnings Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Virpax Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Virpax Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Virpax Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virpax Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Virpax Pharmaceuticals's Price-to-Owner-Earnings falls into.



Virpax Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Virpax Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.7501/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virpax Pharmaceuticals  (NAS:VRPX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Virpax Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Virpax Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Virpax Pharmaceuticals (Virpax Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
Executives
Sheila Mathias officer: Chief Scientific Officer 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Barbara Ruskin director C/O VIRPAX PHARMACEUTICALS, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jerrold Sendrow director C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Eric Floyd director C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Anthony P. Mack director, 10 percent owner, officer: Chief Executive Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Michael F Dubin director C/O VIRPAX PHARMACEUTICALS, 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Gary S Jacob director
Christopher Michael Chipman officer: Chief Financial Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Jeffrey Gudin director, officer: Chief Medical Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Thani Jambulingam director C/O VIRAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Gerald W Bruce officer: EVP, Commercial Operations NITROMED INC, 125 SPRING STREET, LEXINGTON MA 02421
Virpax Pharmaceuticals Llc 10 percent owner C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380